Evidence map›Paper›PMID 27992528›Full record

Observational studyPloS one2016

Colistin Dosage without Loading Dose Is Efficacious when Treating Carbapenem-Resistant Acinetobacter baumannii Ventilator-Associated Pneumonia Caused by Strains with High Susceptibility to Colistin.

Rocío Álvarez-Marín, Rafael López-Rojas, Juan Antonio Márquez, María José Gómez, José Molina, José Miguel Cisneros, Carlos Ortiz-Leyba, Javier Aznar, José Garnacho-Montero, Jerónimo Pachón

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Dose Optimization of Colistin: A Systematic Review.Antibiotics (Basel, Switzerland) · 2021
    Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Rocío Álvarez-MarínClinical Unit of Infectious Diseases, Microbiology and Preventive Medicine Infectious Diseases Research Group Institute of Biomedicine of Seville (IBiS) University of Seville/CSIC/University Hospitals Virgen del Rocio and Virgen Macarena, Seville, Spain.ORCID http://orcid.org/0000-0002-7101-2514
Rafael López-RojasClinical Unit of Infectious Diseases, Microbiology and Preventive Medicine Infectious Diseases Research Group Institute of Biomedicine of Seville (IBiS) University of Seville/CSIC/University Hospitals Virgen del Rocio and Virgen Macarena, Seville, Spain.
Juan Antonio MárquezClinical Unit of Critical Care and Emergencies, Institute of Biomedicine of Seville (IBiS), University Hospital Virgen del Rocío/CSIC/University of Seville, Seville, Spain.
María José GómezClinical Unit of Infectious Diseases, Microbiology and Preventive Medicine Infectious Diseases Research Group Institute of Biomedicine of Seville (IBiS) University of Seville/CSIC/University Hospitals Virgen del Rocio and Virgen Macarena, Seville, Spain.
José MolinaClinical Unit of Infectious Diseases, Microbiology and Preventive Medicine Infectious Diseases Research Group Institute of Biomedicine of Seville (IBiS) University of Seville/CSIC/University Hospitals Virgen del Rocio and Virgen Macarena, Seville, Spain.
José Miguel CisnerosClinical Unit of Infectious Diseases, Microbiology and Preventive Medicine Infectious Diseases Research Group Institute of Biomedicine of Seville (IBiS) University of Seville/CSIC/University Hospitals Virgen del Rocio and Virgen Macarena, Seville, Spain.
Carlos Ortiz-LeybaClinical Unit of Critical Care and Emergencies, Institute of Biomedicine of Seville (IBiS), University Hospital Virgen del Rocío/CSIC/University of Seville, Seville, Spain.
Javier AznarClinical Unit of Infectious Diseases, Microbiology and Preventive Medicine Infectious Diseases Research Group Institute of Biomedicine of Seville (IBiS) University of Seville/CSIC/University Hospitals Virgen del Rocio and Virgen Macarena, Seville, Spain.
José Garnacho-MonteroClinical Unit of Critical Care, University Hospital Virgen Macarena, Seville, Spain.
Jerónimo PachónClinical Unit of Infectious Diseases, Microbiology and Preventive Medicine Infectious Diseases Research Group Institute of Biomedicine of Seville (IBiS) University of Seville/CSIC/University Hospitals Virgen del Rocio and Virgen Macarena, Seville, Spain.
Instituto de Biomedicina de Sevilla · ESHospital Universitario Virgen Macarena · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThis study aims to analyze the mortality and the length of ICU stay (LOS) of A. baumannii VAP compared to respiratory colonization in patients with mechanical ventilation (MV).

methodsA prospective cohort study was performed in an ICU of adult patients (February 2010-June 2011). One hundred patients on MV with A. baumannii in lower respiratory airways were recruited, and classified as VAP or airways colonization according to CPIS criteria, with a punctuation ≥6. LOS, 30-days mortality, A. baumannii bacteremia, and clinical features including antibiotic therapy were recorded. Multivariate analysis (linear and Cox regression) and survival analysis (Kaplan-Meier curves) were performed.

resultsFifty-seven VAP and 43 colonized A. baumannii patients were analyzed. Among the A. baumannii strains, 99% were non-susceptible to carbapenems and the MIC90 of colistin was 0.12 mg/l. Therapy was appropriate in 94.6% of VAP patients, most of them with colistin 6 MIU/day, although in 13 (23.6%) cases colistin was started 48 hours after the onset of VAP. Mortality was similar in both groups (VAP 24.6% vs. colonized 27.9%, p = 0.7). Bacteremia and acute kidney insufficiency were associated with decreased survival (p = 0.02 and p = 0.04, respectively) in VAP patients. LOS was 21.5 (11.5-42.75) vs. 9 (6-22) days for VAP and colonized patients (p = 0.004). VAP (p = 0.003) and age (p = 0.01) were independently related to a longer LOS.

conclusionsMultidrug-resistant A. baumannii VAP treated with colistin does not have a different mortality compared to lower airways colonization, among patients on mechanical-ventilation, in a setting of high susceptibility to colistin of A. baumannii.

Indexed as

BacteremiaCarbapenemsAcinetobacter baumanniiAdultColistinDisease-Free SurvivalDrug Resistance, Multiple, BacterialFemaleFollow-Up StudiesHumansMalePneumonia, Ventilator-AssociatedProspective StudiesSurvival RateCarbapenemsColistin

Identifiers

PMID27992528
PMCPMC5167546
OpenAlexW2563510954

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.